• company
• contact

• Peyronie's Disease
• Plantar Fibromatosis
• Dupuytren's Disease
• Healthcare Professionals

Treatment Options

Doctors have tried many different treatments for Peyronie's disease since it was first described in 1678. The most common treatments can be divided into two basic categories, invasive and non-invasive.

Invasive treatments include:

• Injections of verapamil, interferon, or purified clostridial collagenase into the plaque
• Various stretching devices
• Surgery- usually performed as a last resort due to potential unfavorable outcomes such as impotence and loss of penile length. Penile prosthesis is an option if the patient has severe erectile dysfunction.

Non-invasive options include:

• Transdermal Verapamil 15% Gel
• Iontophoresis of different drugs
• ESWT- Extracorporeal Shock Wave Therapy
• Oral Medications such as vitamin E, colchicine, paraaminobenzoate (Potaba®), tamoxifen, and acetyl-L carnitine

Most doctors agree that a conservative approach to treating Peyronie's disease is preferred. As a result, the least invasive options are typically tried first before moving to invasive procedures or surgery in patients suffering from the most significant cases of Peyronie's disease.

Copyright © 2013 PDLabs Inc. All rights reserved. Privacy Policy.

The information contained in this website is provided for educational purposes only and is not intended to replace discussions with your healthcare provider. All decisions regarding a patients' treatment must be made with a healthcare provider. PDLabs is not an "internet pharmacy" and requires that an appropriate doctor-patient-pharmacist relationship be maintained. PDLabs will not fill prescriptions for patients that do not have a valid patient-doctor relationship.

Transdermal Verapamil 15% Gel is available as a compounded medication exclusively from PDLabs. Transdermal Verapamil 15% Gel is not FDA approved.

Transdermal Verapamil 15% Gel is not for everyone. Patients with specific heart conditions known as atrioventricular (AV) block or Sino-Atrial (SA) block should not use calcium channel blockers such as verapamil. Patients taking the antiarrhythmic drug Tikosyn® (Dofetilide) should not use Transdermal Verapamil 15% Gel.

Patients taking digoxin or cyclosporine should have their drug levels monitored on a regular basis as verapamil may decrease the metabolism and clearance of these drugs. Patients taking antiarrhythmic drugs should consult with their doctor before taking Transdermal Verapamil 15% Gel to ensure it is safe to use. A PDLabs pharmacist can help with this discussion.

The most common side effect reported with Transdermal Verapamil 15% Gel, affecting 3-5% of Peyronie's disease patients, is varying degrees of skin irritation. Some patients using the medication for the first time may experience mild itching/irritation during the first few days of treatment. This is normal and usually resolves within 3-4 days. Other patients may experience more severe contact dermatitis, including itching, burning, redness, or swelling. More persistent or severe irritation can usually be treated with topical corticosteroids. Based on the individual symptoms, PDLabs will work with the patient and prescribing physician to determine the best course of treatment to resolve irritation.